Immunotherapy drug shows promise for tough brain cancers
NCT ID NCT03557359
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested the immunotherapy drug nivolumab (Opdivo) in 35 adults with recurrent or progressive IDH mutant gliomas that had been previously treated with alkylating agents. The main goal was to see if the drug could shrink tumors. The study is now complete, and results will show how many patients responded to treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab (Opdivo)
What this could lead to
If successful, this could point toward a new treatment option for people with recurrent IDH mutant gliomas that have stopped responding to standard chemotherapy.
What could go wrong
This is a small, early-phase trial with only 35 participants and no comparison group, so results may not be definitive. Nivolumab can cause immune-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University Medical Center
New York, New York, 10032, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Miami Cancer Center
Miami, Florida, 33176, United States
-
Weill Cornell Medical College
New York, New York, 10065, United States